On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion.
Reading SUSTAIN 6 (N Engl J Med, 2016) for the population rather than the effect, which I have not done properly before.
The baseline table is more restrictive than the way the trial gets discussed here. Several of the questions in this category come from people who would not have been enrolled.
What is the honest way to describe what the trial says to somebody outside its population?